Thus, there were few co-occurring mutations within the CYSLTR2 mutant cancers (between 5 and 19 coding mutations per sample), intuitively reducing the chance that the enrichment of semaphorin/plexin mutations in CYSLTR2 mutant UM relative to GNAQ/GNA11 mutant UM was a false discovery. The gene discussed is CYSLTR2; the disease is cancer.